BiotechTube

Durvalumab + BA3011 + BA3021 + ENB003 + Toripalimab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ovarian Cancer

Conditions

Ovarian Cancer

Trial Timeline

May 3, 2022 → Dec 31, 2026

NCT ID
NCT04918186

About Durvalumab + BA3011 + BA3021 + ENB003 + Toripalimab

Durvalumab + BA3011 + BA3021 + ENB003 + Toripalimab is a phase 2 stage product being developed by BioAtla for Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04918186. Target conditions include Ovarian Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04918186Phase 2Recruiting

Competing Products

20 competing products in Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
44
Azenosertib + NiraparibZentalis PharmaceuticalsPhase 1/2
33
pemetrexed + topotecanEli LillyPhase 1
33
arzoxifene hydrochlorideEli LillyPhase 2
52
LY4337713Eli LillyPhase 1
33
PrexasertibEli LillyPhase 2
52
Gemcitabine + Oxaliplatin + BevacizumabEli LillyPhase 2
52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
41
Trastzumab Deruxtecan + Bevacizumab + Platinum Based ChemotherapyDaiichi SankyoPhase 2
52
Trastuzumab Deruxtecan + BevacizumabDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
CS-1008 + Paclitaxel + CarboplatinDaiichi SankyoPhase 2
52
OSI-906 + PaclitaxelAstellas PharmaPhase 1/2
41
Enzalutamide 40 MGAstellas PharmaPhase 2
52
ASP0739Astellas PharmaPhase 1/2
41
IMAB027Astellas PharmaPhase 1
33
OSI-211 (Liposomal Lurtotecan)Astellas PharmaPhase 2
52
Triptorelin for Injection + Recombinant Human Choriogonadotropin alfa Solution for Injection + Progesterone Soft CapsulesSun PharmaceuticalPhase 3
77
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52

Other Products from BioAtla

CAB-AXL-ADC + PD-1 inhibitorPhase 2
44
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabPhase 2
44
CAB-AXL-ADC + PD-1 inhibitorPhase 1/2
33
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)Phase 1/2
33
CAB-ROR2-ADC + PD-1 inhibitorPhase 1/2
33